CO5271661A1 - Pirimidonas de bifenilo con actividad contra aterosclerosis - Google Patents
Pirimidonas de bifenilo con actividad contra aterosclerosisInfo
- Publication number
- CO5271661A1 CO5271661A1 CO01011957A CO01011957A CO5271661A1 CO 5271661 A1 CO5271661 A1 CO 5271661A1 CO 01011957 A CO01011957 A CO 01011957A CO 01011957 A CO01011957 A CO 01011957A CO 5271661 A1 CO5271661 A1 CO 5271661A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- alkoxy
- mono
- aryl
- halogen
- Prior art date
Links
- 150000008318 pyrimidones Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 30
- 125000003545 alkoxy group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 7
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004171 alkoxy aryl group Chemical group 0.000 abstract 1
- 125000005157 alkyl carboxy group Chemical group 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000005605 benzo group Chemical group 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004185 ester group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- -1 perfluoro Chemical group 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de formula (I): <EMI FILE="01011957_1" ID="1" IMF=JPEG >en la que:Ra es hidrógeno, halógeno, alquilo C(1-3), alcoxilo-C(1-3), hidroxialquilo C(1-3), alquilC(1-3)tio, alquil C(1-3)-sulfinilo, aminoalquiloC(1-3), mono- o di-alquilC(1-3), aminoalquilo C(1-3), alquilC(1-3) carbonilaminoalquiloC(1-3), alcoxiC(1-3) alquil C(1-3) carbonilaminoalquilo C(1-3), alquil C(1-3)sulfonilaminoalquilo C(1-3), alquil C(1-3)carboxilo, o alquilC(1-3)-carboxialquiloC(1-3),Rb es hidrógeno, halógeno, alquilo C(1-3) o hidroxialquiloC(1-3), con la condición de que Ra y Rb no sean simultáneamente hidrógeno; oRa y Rb son conjuntamente (CH2)n, en el que n es 3 ó 4, para formar con los átomos de carbono de anillo de pirimidina a los que están unidos, un anillo carbocíclico fusionado de 5 o 6 miembros; o Ra y Rb junto con los átomos de carbono de anillo de pirimidina a los que están unidos, forman un anillo benzo o heteroarílico fusionado que esta opcionalmente sustituido con 1, 2 , 3 o 4 sustituyentes, que pueden ser iguales o diferentes seleccionados entre halógeno, alquilo C(1-4), ciano, alcoxiloC(1-4), alquilC(1-4), tio o de mono- a perfluoro- alquilo C(1-4);Rc es hidrógeno o alquilo C(1-3);R2 es un grupo arilo o heteroarilo opcionalmente sustituido con 1, 2, 3, ó 4 sustituyentes que pueden ser iguales o diferentes seleccionados entre alquiloC(1-18), alcoxilo-C(1-18), alquilC(1-18)tio, aril-alcoxilo C(1-18), hidroxilo, halógeno, CN, COR6, carboxilo, COOR6, NR6COR7, CONR8R9, SO2NR8R9, NR6SO2R7, NR8R9, de mono-a perfluoro alquilo C(1-4), de mono a perfluoro-alcoxiC(1-4) arilo, y aril-alquilo C(1-4); R3 es hidrógeno, alquiloC(1-6), que puede estar no sustituido o sustituido con 1, 2 o 3 sustituyentes seleccionados entre hidroxilo, halógeno, OR6, COR6, - 2 - carboxilo, COOR6, CONR8R9, NR8R9, NR8COR9, mono- o di-(hidroxialquil C(1-6)) amino y N -hidroxialquil C(1-6) -N-alquil C(1-6) amino; o R3 es Het-alquiloC(0-4), en el que Het es un anillo heterocíclico de 5 a 7 miembros que comprende N y, opcionalmente O o S, unido a través de un átomo de carbono anular y en el que N puede estar sustituido con COR6, COOR6, CONR8R9, o alquiloC(1-6), opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados entre hidroxilo, halógeno, OR6, COR6, carboxilo, COOR6, CONR8R9 o NR8R9;R4 es un anillo arílico o heteroarílico opcionalmente sustituido con 1, 2, 3 o 4 sustituyentes que pueden ser iguales o diferentes seleccionados entre alquilo C(1-18), alcoxilo C(1-18) alquilC(1-18), tio, aril-alcoxiloC(1-18), hidroxilo, halógeno, CN, COR6, carboxilo, COOR6, NR6COR7, CONR8R9, SO2NR8R9, NR6SO2R7, NR8R9, de mono a prefluoro-alquilo C(1-4), y de mono- a perfluoro-alcoxilo C(1-4);R5 es un anillo arílico o heteroarílico que además está opcionalmente sustituido con 1, 2, 3 ó 4 sustituyentes que pueden ser iguales o diferentes, seleccionados entre alquilo C(1-18), (preferiblemente alquilo C(1-6)), alcoxiloC(1-18) (preferiblemente alcoxiC(1-6)), alquilC(1-18)tio(preferiblemente alquilC(1-6)tio), aril alcoxilo C(1-18), (preferiblemente aril-alcoxi C(1-6)), hidroxilo, halógeno, CN, COR6, carboxilo, COOR6, CONR8R9, NR6COR7, SO2NR8R9, NR6SO2R7, NR8R9, de mono- a perfluoro-alquilo C(1-4), y de mono- a perfluoro-alcoxilo C(1-4);R6 y R7 son independientemente hidrógeno o alquilo C(1-20), tal como, por ejemplo, alquilo C(1-4);R8 y R9, que pueden ser iguales o diferentes son seleccionados cada uno entre hidrógeno y alquilo C(1-12), o R8 y R9 junto con el nitrógeno al estan unidos forman un anillo de 5 a 7 miembros que contiene opcionalmente uno o mas heteroátomos adicionales seleccionados entre oxígeno, nitrógeno y azufre, y está opcionalmente sustituido con uno o dos sustituyentes seleccionados entre hidroxilo, oxo, alquilo C(1-4), alquil C(1-4)CO, arilo, y aralquilo; o R8 y R9, que pueden ser iguales o diferentes, son seleccionados cada uno, entre CH2R10, CHR11CO2H o una sal del mismo en los que:R10 es COOH o una sal del mismo, COOR12, CONR6R7, CN, CH2OH o CH2OR6;R11 es una cadena lateral aminoácido tal como CH2OH de serina;R12 es alquilo C(1-4) o un grupo éster farmacéuticamente aceptable e hidrolizable in vivo;N es un número entero de 1 a 4;X es O o S;Y es (CH2)p(O)q en el que p es 1, 2 o 3 y q es 0, o p es 2 ó 3 y q es 1; yZ es O o un enlace.1 Un compuesto de la fórmula (IA):<EMI FILE="01011957_2" ID="2" IMF=JPEG >en la que: Ra, Rb, Rc,n, R2, R3, R4 ,R5 y X son como se definieron en la reivindicación 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0003636A GB0003636D0 (en) | 2000-02-16 | 2000-02-16 | Novel compounds |
| GB0101437A GB0101437D0 (en) | 2001-01-19 | 2001-01-19 | Novel Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5271661A1 true CO5271661A1 (es) | 2003-04-30 |
Family
ID=26243663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO01011957A CO5271661A1 (es) | 2000-02-16 | 2001-02-15 | Pirimidonas de bifenilo con actividad contra aterosclerosis |
Country Status (31)
| Country | Link |
|---|---|
| US (10) | US20020103213A1 (es) |
| EP (2) | EP1686119B1 (es) |
| JP (1) | JP4095804B2 (es) |
| KR (1) | KR100781425B1 (es) |
| CN (1) | CN1179952C (es) |
| AR (1) | AR030190A1 (es) |
| AT (2) | ATE333446T1 (es) |
| AU (2) | AU2001235466B2 (es) |
| BG (1) | BG66014B1 (es) |
| BR (1) | BRPI0108396B1 (es) |
| CA (1) | CA2400554C (es) |
| CO (1) | CO5271661A1 (es) |
| CY (2) | CY1105649T1 (es) |
| CZ (1) | CZ304450B6 (es) |
| DE (2) | DE60121550T2 (es) |
| DK (2) | DK1263740T3 (es) |
| ES (2) | ES2330552T3 (es) |
| GC (1) | GC0000221A (es) |
| HU (1) | HU229479B1 (es) |
| IL (2) | IL151236A (es) |
| MX (1) | MXPA02008062A (es) |
| MY (1) | MY135732A (es) |
| NO (1) | NO324691B1 (es) |
| NZ (1) | NZ520752A (es) |
| PL (1) | PL209824B1 (es) |
| PT (2) | PT1263740E (es) |
| SI (2) | SI1263740T1 (es) |
| SK (1) | SK287296B6 (es) |
| TW (1) | TW550259B (es) |
| UA (1) | UA73762C2 (es) |
| WO (1) | WO2001060805A1 (es) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001235466B2 (en) * | 2000-02-16 | 2004-04-22 | Glaxo Group Limited | Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors |
| GB0024807D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| WO2002032863A1 (en) * | 2000-10-20 | 2002-04-25 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
| GB0119795D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel process |
| GB0119793D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
| GB0127139D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127143D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127141D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham Plc | Novel compounds |
| GB0127140D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| EP1466904A4 (en) * | 2001-12-28 | 2005-12-14 | Takeda Pharmaceutical | BIARYL CONNECTION AND ITS USE |
| US6939863B2 (en) | 2002-01-04 | 2005-09-06 | Wei-Jan Chen | Prevention of atherosclerosis and restenosis |
| GB0208279D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| US20050227974A9 (en) * | 2002-08-01 | 2005-10-13 | Euro-Celtique S.A. | Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
| JP4366122B2 (ja) * | 2003-06-24 | 2009-11-18 | 日立オムロンターミナルソリューションズ株式会社 | 紙葉類搬送装置 |
| GB0320522D0 (en) * | 2003-09-02 | 2003-10-01 | Glaxo Group Ltd | Formulation |
| EP2314576A1 (en) | 2003-11-05 | 2011-04-27 | F.Hoffmann-La Roche Ag | Phenyl derivatives as PPAR agonists |
| JP4812751B2 (ja) | 2004-04-16 | 2011-11-09 | グラクソ グループ リミテッド | Ｌｐ−ＰＬＡ２活性およびＬｐ−ＰＬＡ２活性阻害を検出する方法 |
| US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
| AU2005244104B2 (en) | 2004-05-08 | 2012-03-15 | Novartis International Pharmaceutical Ltd. | 4,5-disubstituted-2-aryl pyrimidines |
| DE102004061005A1 (de) * | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Cycloalkyl-1,2,4-triazin-5(2H)-one |
| US20080090851A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| US20080090852A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| US7705005B2 (en) * | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| BRPI0810336A2 (pt) * | 2007-05-11 | 2019-03-19 | The Trustees Of The University Of Pennsylvania | "método para tratar e/ou prevenir úlceras de pele em um indivíduo" |
| KR101730290B1 (ko) * | 2007-05-11 | 2017-04-25 | 토마스 제퍼슨 유니버시티 | 신경변성 질환 및 장애의 치료 및 예방 방법 |
| US8637524B2 (en) | 2009-07-28 | 2014-01-28 | Auspex Pharmaceuticals, Inc | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 |
| AR081399A1 (es) * | 2010-05-17 | 2012-08-29 | Glaxo Group Ltd | Proceso para preparar un compuesto de pirimidinona, compuestos intermediarios en dicho proceso y procesos para repararlos. |
| KR101931628B1 (ko) | 2010-06-18 | 2019-03-13 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | 항바이러스 화합물에 대한 타켓인 pla2g16 |
| EP2649050A4 (en) * | 2010-12-06 | 2014-04-23 | Glaxo Group Ltd | LINKS |
| CN104478812A (zh) * | 2010-12-06 | 2015-04-01 | 葛兰素集团有限公司 | 用于治疗由Lp-PLA2介导的疾病或病症的嘧啶酮化合物 |
| CA2820408C (en) * | 2010-12-06 | 2018-03-06 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2 |
| WO2012080497A2 (en) | 2010-12-17 | 2012-06-21 | Glaxo Group Limited | Methods of treatment and prevention of eye diseases |
| CN102643269B (zh) * | 2011-02-21 | 2014-07-23 | 天津药物研究院 | 一类含吡唑结构的磷脂酶a2抑制剂及用途 |
| WO2012122707A1 (zh) * | 2011-03-16 | 2012-09-20 | 中国科学院上海药物研究所 | 季铵盐类化合物、其制备方法、药物组合物及用途 |
| WO2012129792A1 (zh) * | 2011-03-30 | 2012-10-04 | 中国科学院上海药物研究所 | 嘧啶酮类化合物、其制备方法及药物组合物和用途 |
| WO2013000267A1 (zh) | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | 唑类杂环化合物、其制备方法、药物组合物和用途 |
| CN103827116B (zh) * | 2011-07-27 | 2016-08-31 | 葛兰素集团有限公司 | 用作LP-PLA2抑制剂的2,3-二氢咪唑并[1,2-c]嘧啶-5(1H)-酮化合物 |
| JP2014521611A (ja) | 2011-07-27 | 2014-08-28 | グラクソ グループ リミテッド | Ｌｐ−ＰＬＡ２阻害剤としての２，３−ジヒドロイミダゾ［１，２−ｃ］ピリミジン−５（１Ｈ）−オン化合物の使用 |
| JP2014521625A (ja) | 2011-07-27 | 2014-08-28 | グラクソ グループ リミテッド | 二環式ピリミドン化合物 |
| JP2016505053A (ja) | 2013-01-25 | 2016-02-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｌｐ‐ＰＬＡ２の阻害剤としての二環式ピリミドン化合物 |
| WO2014114694A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
| CA2899124A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
| WO2015087239A1 (en) | 2013-12-11 | 2015-06-18 | Ranbaxy Laboratories Limited | Processes for the preparation of darapladib and its intermediates |
| WO2015092687A2 (en) | 2013-12-17 | 2015-06-25 | Ranbaxy Laboratories Limited | Process for the purification of darapladib |
| WO2015114479A1 (en) | 2014-01-28 | 2015-08-06 | Ranbaxy Laboratories Limited | Crystalline forms of darapladib oxalate, adipate, succinate, phosphate, sulphate, fumaratetartrate, nitrate and borate |
| WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| MX389591B (es) | 2014-08-29 | 2025-03-20 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA |
| CN105777653A (zh) * | 2014-12-26 | 2016-07-20 | 中国科学院上海药物研究所 | 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物 |
| CN104840963B (zh) * | 2015-05-26 | 2018-02-16 | 河北东康生物科技有限公司 | 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用 |
| WO2016198691A1 (en) * | 2015-06-11 | 2016-12-15 | Basilea Pharmaceutica Ag | Efflux-pump inhibitors and therapeutic uses thereof |
| WO2017106396A1 (en) * | 2015-12-16 | 2017-06-22 | Bristol-Myers Squibb Company | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
| US10878307B2 (en) * | 2016-12-23 | 2020-12-29 | Microsoft Technology Licensing, Llc | EQ-digital conversation assistant |
| ES2907130T3 (es) | 2017-09-26 | 2022-04-22 | Inst Nat Sante Rech Med | Darapladib radiomarcado, análogos del mismo y su uso como compuestos para la obtención de imágenes |
| CN110746445B (zh) * | 2019-10-16 | 2021-03-16 | 深圳海关食品检验检疫技术中心 | 一种头孢哌酮氘代内标物的制备方法 |
| WO2021089032A1 (zh) | 2019-11-09 | 2021-05-14 | 上海赛默罗生物科技有限公司 | 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| EP4257133A1 (en) | 2022-04-05 | 2023-10-11 | Institut Pasteur | Oxo-azaheterocyclic derivatives for use in the treatment of malaria |
| CN119191998A (zh) * | 2024-11-29 | 2024-12-27 | 浙江省质量科学研究院 | 一种双羟乙基氨基丙基羟乙基十六胺的合成方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69423436T2 (de) | 1993-06-25 | 2000-09-07 | Smithkline Beecham P.L.C., Brentford | An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie |
| EP1634953A3 (en) * | 1993-10-06 | 2006-06-28 | ICOS Corporation | Platelet-activating factor acethylhydrolase |
| GB9421816D0 (en) | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
| SK80397A3 (en) | 1994-12-22 | 1998-01-14 | Smithkline Beecham Plc | Substituted azetidin-2-ones, preparation method thereof, farmaceutical compositions and their use |
| CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
| CN1197452A (zh) | 1995-07-01 | 1998-10-28 | 史密丝克莱恩比彻姆有限公司 | 用于治疗动脉粥样硬化的氮杂环丁烷酮衍生物 |
| AU7216996A (en) | 1995-09-29 | 1997-04-28 | Smithkline Beecham Plc | A paf-acetylhydrolase and use in therapy |
| JP2000502079A (ja) | 1995-12-08 | 2000-02-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体 |
| JP2000505063A (ja) | 1995-12-08 | 2000-04-25 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症の治療のためのアゼチジノン化合物 |
| CA2252696A1 (en) | 1996-04-26 | 1997-11-06 | Deirdre Mary Bernadette Hickey | Azetidinone derivatives for the treatment of atherosclerosis |
| GB9608649D0 (en) | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
| GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| US6417192B1 (en) | 1997-11-06 | 2002-07-09 | Smithkline Beecham P.L.C. | Pyrimidinone compounds and pharmaceutical compositions containing them |
| ATE251613T1 (de) | 1998-08-21 | 2003-10-15 | Smithkline Beecham Plc | Pyrimidinonderivate zur behandlung von atheroscleros |
| GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
| IL146210A0 (en) | 1999-05-01 | 2002-07-25 | Smithkline Beecham Plc | Pyrimidinone compounds |
| GB9910378D0 (en) | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
| AU2001235466B2 (en) * | 2000-02-16 | 2004-04-22 | Glaxo Group Limited | Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors |
| GB0024807D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| GB0024808D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
-
2001
- 2001-02-13 AU AU2001235466A patent/AU2001235466B2/en not_active Ceased
- 2001-02-13 EP EP06075890A patent/EP1686119B1/en not_active Expired - Lifetime
- 2001-02-13 UA UA2002097389A patent/UA73762C2/uk unknown
- 2001-02-13 CA CA002400554A patent/CA2400554C/en not_active Expired - Fee Related
- 2001-02-13 KR KR1020027010662A patent/KR100781425B1/ko not_active Expired - Fee Related
- 2001-02-13 DK DK01907522T patent/DK1263740T3/da active
- 2001-02-13 MX MXPA02008062A patent/MXPA02008062A/es active IP Right Grant
- 2001-02-13 ES ES06075890T patent/ES2330552T3/es not_active Expired - Lifetime
- 2001-02-13 HU HU0204410A patent/HU229479B1/hu not_active IP Right Cessation
- 2001-02-13 PT PT01907522T patent/PT1263740E/pt unknown
- 2001-02-13 SI SI200130614T patent/SI1263740T1/sl unknown
- 2001-02-13 DE DE60121550T patent/DE60121550T2/de not_active Expired - Lifetime
- 2001-02-13 AU AU3546601A patent/AU3546601A/xx active Pending
- 2001-02-13 WO PCT/EP2001/001515 patent/WO2001060805A1/en not_active Ceased
- 2001-02-13 DE DE60139429T patent/DE60139429D1/de not_active Expired - Lifetime
- 2001-02-13 ES ES01907522T patent/ES2267714T3/es not_active Expired - Lifetime
- 2001-02-13 CN CNB01806521XA patent/CN1179952C/zh not_active Expired - Fee Related
- 2001-02-13 JP JP2001560190A patent/JP4095804B2/ja not_active Expired - Fee Related
- 2001-02-13 DK DK06075890T patent/DK1686119T3/da active
- 2001-02-13 AT AT01907522T patent/ATE333446T1/de active
- 2001-02-13 BR BRPI0108396-1A patent/BRPI0108396B1/pt not_active IP Right Cessation
- 2001-02-13 CZ CZ2002-2768A patent/CZ304450B6/cs not_active IP Right Cessation
- 2001-02-13 PT PT06075890T patent/PT1686119E/pt unknown
- 2001-02-13 PL PL357382A patent/PL209824B1/pl unknown
- 2001-02-13 SI SI200130941T patent/SI1686119T1/sl unknown
- 2001-02-13 AT AT06075890T patent/ATE437862T1/de active
- 2001-02-13 NZ NZ520752A patent/NZ520752A/en not_active IP Right Cessation
- 2001-02-13 SK SK1177-2002A patent/SK287296B6/sk not_active IP Right Cessation
- 2001-02-13 EP EP01907522A patent/EP1263740B1/en not_active Expired - Lifetime
- 2001-02-14 AR ARP010100659A patent/AR030190A1/es not_active Application Discontinuation
- 2001-02-14 GC GCP20011178 patent/GC0000221A/en active
- 2001-02-14 US US09/782,930 patent/US20020103213A1/en not_active Abandoned
- 2001-02-14 MY MYPI20010671A patent/MY135732A/en unknown
- 2001-02-15 CO CO01011957A patent/CO5271661A1/es active IP Right Grant
- 2001-02-15 TW TW090103332A patent/TW550259B/zh not_active IP Right Cessation
-
2002
- 2002-08-13 IL IL151236A patent/IL151236A/en not_active IP Right Cessation
- 2002-08-13 NO NO20023828A patent/NO324691B1/no not_active IP Right Cessation
- 2002-08-26 BG BG107034A patent/BG66014B1/bg unknown
-
2003
- 2003-02-03 US US10/357,238 patent/US6649619B1/en not_active Expired - Lifetime
- 2003-10-27 US US10/694,561 patent/US7153861B2/en not_active Expired - Fee Related
-
2006
- 2006-10-06 CY CY20061101441T patent/CY1105649T1/el unknown
- 2006-11-17 US US11/561,035 patent/US7470694B2/en not_active Expired - Fee Related
- 2006-11-21 US US11/561,926 patent/US7638520B2/en not_active Expired - Fee Related
-
2007
- 2007-03-15 IL IL181957A patent/IL181957A0/en unknown
-
2009
- 2009-01-06 US US12/349,086 patent/US7652019B2/en not_active Expired - Fee Related
- 2009-02-18 US US12/372,837 patent/US20090170877A1/en not_active Abandoned
- 2009-10-12 CY CY20091101045T patent/CY1109484T1/el unknown
-
2010
- 2010-02-18 US US12/707,838 patent/US20100144765A1/en not_active Abandoned
-
2011
- 2011-12-02 US US13/309,941 patent/US8871775B2/en not_active Expired - Fee Related
-
2014
- 2014-10-24 US US14/522,870 patent/US9266841B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5271661A1 (es) | Pirimidonas de bifenilo con actividad contra aterosclerosis | |
| CO5170521A1 (es) | Compuestos farmaceuticos de pirimidinona | |
| CO5251467A1 (es) | Derivados de piperazina | |
| CO5200783A1 (es) | Compuestos terapeuticos | |
| HRP20110957T1 (hr) | Derivati kinolina kao inhibitori fosfodiesteraza | |
| AR035349A1 (es) | Compuestos de pirimidinona, composiciones farmaceuticas que los comprenden, uso de tales compuestos en la fabricacion de medicamentos y proceso para la preparacion de dichos compuestos | |
| AR006906A1 (es) | Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis | |
| CO5280059A1 (es) | Derivados de 2-ox-1-pirrolidina, procewo para prepararlos y sus aplicaciones | |
| AR038341A1 (es) | Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l | |
| PE20091335A1 (es) | Derivados de ftalazinona | |
| AR064547A1 (es) | Derivados de azaspiro como antagonistas del receptor v1a | |
| PE20030762A1 (es) | Compuestos heterociclicos como antagonistas nk1 | |
| AR039226A2 (es) | Compuestos utiles como intermediarios de preparacion y procedimientos | |
| EA199800664A1 (ru) | Замещенные производные 4-гидрокси-фенилалкановой кислоты с агонистической активностью по отношению к ppar-гамма | |
| PE20030703A1 (es) | Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3 | |
| UY32314A (es) | Derivados de 4-fenil-piridina | |
| PE20030273A1 (es) | Derivados de tetrahidroquinolina como moduladores de la hormona foliculo estimulante | |
| UY26943A1 (es) | Derivados de piridina | |
| HRP20030003B1 (en) | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives | |
| RU2008151888A (ru) | Замещенные арилпиперидинилалкиниладенозины в качестве а2аr агонистов | |
| HRP20090071T3 (en) | Indole derivatives and use thereof as kinase inhibitors in particular ikk2 inhibitors | |
| CO5251410A1 (es) | Derivados de nitrilo como inhibidores de la captesina k | |
| PE20050145A1 (es) | Dihidroquinazolinas sustituidas como agentes antivirales | |
| ATE255563T1 (de) | Therapeutisch nützliche chinoline und quinazoline | |
| CO5170529A1 (es) | Derivados de 5-(fenil sustituido)-2-piperazinil-pirimidin-(3,5- bistrifluoro-metil-bencil)-metil-amida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |